Payment overview · 2025
General Payments
$377.73
23 reported records · 9 companies
Healthcare provider profile · identity verified
Arnold W Fleischmann, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1487825808
Verified facts
What the public records show
CMS Open Payments records show Arnold W Fleischmann, M.D. received $377.73 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.32 | 38.5% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.75 | 17.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.23 | 13.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.86 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.08 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.21 | 5.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.86 | 5.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.10 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.32 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.73 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $128.68 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $92.98 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $65.75 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 216 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 202 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
122 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
202 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
211 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 809 | 263 |
| Amlodipine Besylate | Amlodipine Besylate | 760 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 182 |
| Losartan Potassium | Losartan Potassium | 525 | 152 |
| Omeprazole | Omeprazole | 431 | 138 |
| Metformin Hcl | Metformin Hcl | 387 | 126 |
| Lisinopril | Lisinopril | 383 | 127 |
| Gabapentin | Gabapentin | 341 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 340 | 112 |
| Metoprolol Tartrate | Metoprolol Tartrate | 317 | 99 |
| Hydralazine Hcl | Hydralazine Hcl | 304 | 108 |
| Carvedilol | Carvedilol | 295 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 93 |
| Jardiance | Empagliflozin | 216 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 65 |
| Eliquis | Apixaban | 211 | 56 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 202 | 48 |
| Furosemide | Furosemide | 182 | 69 |
| Tramadol Hcl | Tramadol Hcl | 163 | 59 |
| Glipizide | Glipizide | 161 | 55 |
| Ozempic | Semaglutide | 161 | 38 |
| Simvastatin | Simvastatin | 149 | 48 |
| Meloxicam | Meloxicam | 146 | 46 |
| Trazodone Hcl | Trazodone Hcl | 145 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 68 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 46 |
| Famotidine | Famotidine | 134 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 48 |
| Pregabalin | Pregabalin | 124 | 21 |
| Januvia | Sitagliptin Phosphate | 123 | 34 |
| Farxiga | Dapagliflozin Propanediol | 122 | 38 |
| Memantine Hcl | Memantine Hcl | 122 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 38 |
| Alprazolam | Alprazolam | 115 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 114 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 38 |
| Warfarin Sodium | Warfarin Sodium | 102 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 30 |
| Sildenafil Citrate | Sildenafil Citrate | 100 | 22 |
| Allopurinol | Allopurinol | 99 | 29 |
| Nifedipine Er | Nifedipine | 94 | 29 |
| Alendronate Sodium | Alendronate Sodium | 90 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 29 |
| Montelukast Sodium | Montelukast Sodium | 85 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 76 |
| Ibuprofen | Ibuprofen | 78 | 35 |
| Clonidine Hcl | Clonidine Hcl | 77 | 23 |
| Donepezil Hcl | Donepezil Hcl | 76 | 32 |
| Potassium Chloride | Potassium Chloride | 75 | 20 |
| Finasteride | Finasteride | 73 | 26 |
| Atenolol | Atenolol | 67 | 19 |
| Spironolactone | Spironolactone | 61 | 22 |
| Azithromycin | Azithromycin | 59 | 55 |
| Ezetimibe | Ezetimibe | 57 | 23 |
| Sertraline Hcl | Sertraline Hcl | 57 | 24 |
| Ketoconazole | Ketoconazole | 54 | 29 |
| Glimepiride | Glimepiride | 53 | 22 |
| Prednisone | Prednisone | 51 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 19 |
| Clonazepam | Clonazepam | 46 | 16 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 17 |
| Baclofen | Baclofen | 44 | 15 |
| Glipizide Er | Glipizide | 43 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 12 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 17 |
| Lactulose | Lactulose | 40 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 12 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 17 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Naproxen | Naproxen | 26 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | 13 |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | 11 |
| Temazepam | Temazepam | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | 12 |
| Nystatin | Nystatin | 20 | 14 |
| Ciclopirox | Ciclopirox | 19 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 12 |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Cephalexin | Cephalexin | 11 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.73 · 23 records | Amgen Inc. | AIRSUPRA, CAPVAXIVE, JARDIANCE, KRYSTEXXA, MOUNJARO, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error